These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Lower respiratory tract illness and RSV prophylaxis in very premature infants. Lacaze-Masmonteil T; Truffert P; Pinquier D; Daoud P; Goldfarb G; Vicaut E; Fauroux B Arch Dis Child; 2004 Jun; 89(6):562-7. PubMed ID: 15155404 [TBL] [Abstract][Full Text] [Related]
25. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit? Geskey JM; Ceneviva GD; Brummel GL; Graff GR; Javier MC Clin Ther; 2004 Dec; 26(12):2130-7. PubMed ID: 15823776 [TBL] [Abstract][Full Text] [Related]
26. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Andabaka T; Nickerson JW; Rojas-Reyes MX; Rueda JD; Bacic Vrca V; Barsic B Cochrane Database Syst Rev; 2013 Apr; (4):CD006602. PubMed ID: 23633336 [TBL] [Abstract][Full Text] [Related]
27. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile? Hashmi NA; Cosgrove JF; MacMahon P Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917 [TBL] [Abstract][Full Text] [Related]
28. Evaluation of the Financial and Health Burden of Infants at Risk for Respiratory Syncytial Virus. Blake SM; Tanaka D; Bendz LM; Staebler S; Brandon D Adv Neonatal Care; 2017 Aug; 17(4):292-298. PubMed ID: 27926583 [TBL] [Abstract][Full Text] [Related]
30. Palivizumab for Infants < 29 Weeks in Hong Kong without a Clear-Cut Season for Respiratory Syncytial Virus Infection-A Cost-Effectiveness Analysis. Lee SR; Kwok KL; Ng DKK; Hon KL J Trop Pediatr; 2018 Oct; 64(5):418-425. PubMed ID: 29106671 [TBL] [Abstract][Full Text] [Related]
31. The use of palivizumab monoclonal antibody to control an outbreak of respiratory syncytial virus infection in a special care baby unit. Cox RA; Rao P; Brandon-Cox C J Hosp Infect; 2001 Jul; 48(3):186-92. PubMed ID: 11439005 [TBL] [Abstract][Full Text] [Related]
32. Respiratory syncytial virus (RSV) immune globulin and palivizumab for prevention of RSV infection. Robinson RF; Nahata MC Am J Health Syst Pharm; 2000 Feb; 57(3):259-64. PubMed ID: 10674778 [TBL] [Abstract][Full Text] [Related]
34. Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey. Oncel MY; Mutlu B; Kavurt S; Baş AY; Demirel N; Akyol M; Erdeve O; Dilmen U Turk J Pediatr; 2012; 54(4):344-51. PubMed ID: 23692714 [TBL] [Abstract][Full Text] [Related]
35. RSV immune globulin prophylaxis: is an ounce of prevention worth a pound of cure? Moler FW Pediatrics; 1999 Sep; 104(3 Pt 1):559-60. PubMed ID: 10469785 [No Abstract] [Full Text] [Related]
36. Decline in respiratory syncytial virus hospitalizations in a region with high hospitalization rates and prolonged season. Singleton RJ; Bruden D; Bulkow LR; Varney G; Butler JC Pediatr Infect Dis J; 2006 Dec; 25(12):1116-22. PubMed ID: 17133156 [TBL] [Abstract][Full Text] [Related]
37. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173 [TBL] [Abstract][Full Text] [Related]
38. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage. Romero JR Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452 [TBL] [Abstract][Full Text] [Related]